ALX On­col­o­gy to make case for ac­cel­er­at­ed ap­proval with new evor­pacept da­ta in gas­tric can­cer

ALX On­col­o­gy is forg­ing ahead with a treat­ment ap­proach that has long been aban­doned by oth­er drug­mak­ers, eye­ing a po­ten­tial ac­cel­er­at­ed ap­proval path­way for its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER